|Articles|November 17, 2020
Insmed’s Fast and Successful Study Builds
Author(s)Veeva
Insmed had a late-breaking strategy change that challenged their timelines. Learn how they incorporated significant protocol changes and still hit their FPI deadline.
Trending on Applied Clinical Trials Online
1
Beyond Patient Centricity: What Rare Disease Research Gets Right
2
What This Study Means for Sponsors Still Struggling to Justify RBQM at Scale
3
ACT Brief: Hidden RBQM Value, Rare Disease Patient Partnership, and Safety Perception in IBD
4
The Unquantified Value of RBQM: Reduced Rework, Data Integrity, and Inspection Readiness
5